×
Fulvestrant + Anastrozole Improves Long-Term PFS and OS vs Anastrozole Alone in Women With Postmenopausal Metastatic Breast Cancer
https://www.practiceupdate.com/content/sabcs-2017nbspfulvestrant-anastrozole-improves-long-term-pfs-and-os-vs-anastrozole-alone-in-women-with-postmenopausal-metastatic-breast-cancer/61146/62

Dec 8th, 2017 - Fulvestrant + anastrozole has been shown to improve long-term progression-free and overall survival vs anastrozole alone in women with postmenopausal metastatic breast cancer, despite the use of fulvestrant at a lower dose than approved, and despite substantial crossover to fulvestrant after progression with anastrozole alone.

Abstract P6-11-02: Voice of cancer patients: Analysis of patient concerns regarding scalp cooling devices for prevention of chemotherapy induced alopecia
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-02

Aug 28th, 2018 - Adjuvant chemotherapies for breast cancer cause hair loss in majority of patients. Although Chemo Induced Alopecia (CIA) is temporary, is distressing for many patients and about 7% patients treated with docetaxel experience permanent hair loss. Scalp cooling devices (SCDs) have been shown to reduce hair loss in patients receiving chemo. Many patients share their experiences in online forums as ...

Abstract P6-11-06: Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients: A retrospective, comprehensive review of 330 cases of Brazil
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-06

Aug 29th, 2018 - Background: Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of many chemotherapy (CT) agents. New strategies for prevention of CIA have been studied. Scalp cooling has been reported to prevent CIA. We conducted a retrospective study aimed to assess the efficacy of scalp cooling in preventing CIA among women receiveing chemotherapy for breast cancer. Methods: Was included cli...

Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide
https://www.onclive.com/conference-coverage/sabcs-2017/genebased-biomarker-identifies-patients-with-breast-cancer-more-likely-to-respond-to-enzalutamide

Dec 8th, 2017 - Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

Lapatinib plus trastuzumab improves outcomes in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155150/breast-cancer/lapatinib-plus-trastuzumab-improves-outcomes-her2

Dec 27th, 2017 - Results from CALGB 40601 conflict with those from two larger trials that failed to find a benefit for dual HER2 blockade in treating HER2+ breast cancer.

High rate of arm morbidity in young breast cancer survivors
https://www.mdedge.com/oncologypractice/article/154705/breast-cancer/high-rate-arm-morbidity-young-breast-cancer-survivors

Dec 18th, 2017 - Undergoing axillary lymph node dissection (ALND) is more likely to result in arm swelling and decreased range of arm motion in young breast cancer patients, as compared with having a sentinel lymph node biopsy (SLNB), according to new findings.

Modest Weight Loss Cuts Postmenopausal Breast Cancer Risk
http://www.medscape.com/viewarticle/889854

Dec 11th, 2017 - Women who lose just 5% of their body weight after the menopause may experience a significant reduction in their risk of developing breast cancer vs women with stable weight, say US researchers.

Abstract P6-11-08: Chemotherapy-induced peripheral neuropathy and quality of life among breast cancer survivors
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-08

Aug 30th, 2018 - Introduction: Breast cancer survivors are at risk for long-term chemotherapy-induced peripheral neuropathy (PN), which has few treatment options and can affect quality of life. We examined 1) the presence and severity of PN and its correlates among 442 metastatic (MBC) and 238 breast cancer (BC) survivors who received chemotherapy, and 2) provider communication, preparation, and confidence in m...

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer
https://www.cancertherapyadvisor.com/breast-cancer/abemaciclib-benefit-breast-cancer-poor-prognostic-markers-risk/article/713426/

Dec 11th, 2017 - This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer
https://ecancer.org/conference/966-sabcs-2017/news/12915-sabcs-2017--phase-iii-trial-data-supports-current-standard-12-month-adjuvant-trastuzumab-for-her2-positive-breast-cancer.php

Dec 7th, 2017 - Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, ...

Abstract P6-11-14: Safety and effectiveness of sensor-controlled scalp cooling to prevent alopecia in primary breast cancer patients receiving neoadjuvant or adjuvant epirubicin, taxanes, or both
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-14

Sep 9th, 2018 - Background: Chemotherapy (Ctx)-induced alopecia (CIA), produces a deep psychological distress in many women involved. Sensor-controlled scalp cooling (SCSC) is now approved by the FDA due to both its effectiveness and safety to prevent CIA demonstrated in two randomized trials in patients (pts) with primary breast cancer (PBC). However, SCSC is still infrequently used in many countries due to p...

Ribociclib Doubles Progression-Free Survival in Premenopausal Breast Cancer
http://www.ascopost.com/issues/december-25-2017/ribociclib-doubles-progression-free-survival-in-premenopausal-breast-cancer/

Dec 25th, 2017 - PREMENOPAUSAL WOMEN with hormone receptor–positive, HER2-negative advanced breast cancer benefited substantially from the addition of ribociclib (Kisqali) to first-line endocrine therapy plus medical ovarian suppression, according to results from the MONALEESA-7 study.

Researchers quantify presence of immunotherapy biomarkers in breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B4ee9505a-d5b1-4da3-b899-d6c77ebc5a22%7D/researchers-quantify-presence-of-immunotherapy-biomarkers-in-breast-cancer

Dec 8th, 2017 - Although a minority of patients with invasive breast cancer expressed microsatellite instability, high tumor mutational load or PD-L1 expression, these biomarkers may elucidate the benefit of immune checkpoint inhibitors for the disease, according to results of a retrospective data analysis presented at the San Antonio Breast Cancer Symposium.

Abstract P5-22-07: Upgrade to high risk lesions, in situ and invasive cancer among women with benign papillary lesions diagnosed on image-guided core needle biopsy (IGCNB)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-07

Dec 15th, 2018 - Background: Currently there is no consensus regarding the management of benign papillary breast lesions diagnosed on IGCNB. Recommendations vary as to whether all IGCNB papillary lesions require surgical excision or if IGCNB alone is adequate to confirm a benign diagnosis and patients can be followed with imaging. Aims: To estimate percentage of patients with benign papilloma on IGNB who on sur...

Ribociclib Improves PFS by 10.8 Months in HR+/HER2- Premenopausal Breast Cancer
https://www.onclive.com/conference-coverage/sabcs-2017/ribociclib-improves-pfs-by-108-months-in-hrher2-premenopausal-breast-cancer

Dec 6th, 2017 - Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-22

Dec 16th, 2018 - Introduction: Close to 65% of BRCA mutation carriers do not choose prophylactic mastectomy, despite their high breast cancer risk. Breast reduction mammoplasty is a surgical technique shown to reduce breast cancer risk and can be modified to target specific areas of the breast. We wondered if a majority of tumors in BRCA mutation carriers would be confined to one quadrant, allowing for the use ...

Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-18

Sep 12th, 2018 - Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is essential to preserve quality of life in cancer patients receiving highly emetogenic chemotherapy (HEC) such as doxorubicin-cyclophosphamide (AC) or cisplatin. Recently, new drugs (e.g. fosaprepitant and newer neurokinin 1 receptor antagonists [NK1RAs], rolapitant and netupitant) and updated guidelines for antiemetic use ...

Abstract P5-22-20: Oncologic safety of endoscopic assisted breast surgery compared with conventional breast surgery: An analysis of 1295 primary operable breast cancer patients from single institute
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-20

Dec 17th, 2018 - Background:Endoscopy-assisted breast surgery (EABS) performed through minimal axillary and/or periareolar incisions is a possible alternative to open surgery for certain patients with breast cancer. In this study, we report the oncologic safety results of EABS compared with conventional breast surgery (CBS). Methods: The medical records of patients who underwent EABS for breast cancer during th...

Statins May Up Breast Cancer-Specific and Overall Survival
http://www.medscape.com/viewarticle/889813

Dec 8th, 2017 - Statins may improve breast cancer outcomes whether women take them before or after their diagnosis and extend overall survival as well.

Abstract P5-22-23: Electrochemotherapy : A new local therapy for cutaneous metastases of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-23

Dec 18th, 2018 - Background : Electrochemotherapy (ECT) is a new local therapy combining the administration of an intravenous chemotherapy (bleomycin) followed by the direct application of electric pulses by an electrode to the treated areas. Electric pulses transiently permeabilize the membrane of the tumor cell ( electroporation), improving intracellular diffusion of a poorly permeant chemotherapeutic agent, ...